Abstract
Methods 25 JDM patients followed at the Pediatric Rheumatology Unit of our tertiary University Hospital were compared to 25 healthy controls according to demographic data, fasting lipoproteins, glycemia and insulin, anti-LPL antibodies and muscle enzymes. All patients were evaluated by the same pediatric rheumatologist in order to evaluate the following JDM scores: Disease Activity Score (DAS), Childhood Myositis Assessment Scale(CMAS), Manual Muscle Testing(MMT), Myositis Disease Activity Assessment Analogue Scale(MYOACT) and Myositis Intention To Treat Activity Index (MYTAX).
Highlights
Juvenile dermatomyositis (JDM) patients may present many risk factors for dyslipidemia such as chronic inflammation and corticosteroid therapy
25 JDM patients followed at the Pediatric Rheumatology Unit of our tertiary University Hospital were compared to 25 healthy controls according to demographic data, fasting lipoproteins, glycemia and insulin, anti-LPL antibodies and muscle enzymes
All patients were evaluated by the same pediatric rheumatologist in order to evaluate the following JDM scores: Disease Activity Score (DAS), Childhood Myositis Assessment Scale(CMAS), Manual Muscle Testing(MMT), Myositis Disease Activity Assessment Analogue Scale(MYOACT) and Myositis Intention To Treat Activity Index (MYTAX)
Summary
Juvenile dermatomyositis (JDM) patients may present many risk factors for dyslipidemia such as chronic inflammation and corticosteroid therapy. The concomitant evaluation of lipid profile, antilipoprotein lipase antibody (anti-LPL), clinical and laboratory assessments, and treatment have not been performed. Aim To evaluate dyslipidemia in JDM patients and healthy controls
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
